Emanuela Romano

12PUBLICATIONS

86CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)AllergyTumour immunologyPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jun 25, 2026

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

|Jun 11, 2025

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Sep 23, 2024

At the Interface of Tumor-Associated Macrophages and Fibroblasts: Immune-Suppressive Networks and Emerging Exploitable Targets.

Eleonora Timperi, Hugo Croizer, Darya Khantakova

|Sep 03, 2024

Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.

Toulsie Ramtohul, Victoire Lepagney, Claire Bonneau

|Apr 01, 2024

Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer.

Hugo Croizer, Rana Mhaidly, Yann Kieffer

|Dec 12, 2023

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

Pageof 2

Frequent Collaborators

Laurence Buisseret

Anne Vincent-Salomon

Christos Sotiriou

Martine Piccart-Gebhart

3 joint publications

Fatima Mechta-Grigoriou

Paulus Kristanto

Roberto Salgado

Elisa Agostinetto

Michail Ignatiadis

Eleonora Timperi

Frequent Collaborators

Laurence Buisseret

Anne Vincent-Salomon

Christos Sotiriou

Martine Piccart-Gebhart